Home > Transparency Disclosures
Relations with patient associations
Relatie met patiëntenverenigingen
Relations avec les associations de patients
Zusammenarbeit mit Patientenorganisationen
Information regarding Intercept’s support for patient associations in Belgium can be found by consulting the Belgian transparency website (https://www.betransparent.be).
Intercept’s ondersteuning van patiëntenorganisaties in België is te vinden in het Belgische transparantieplatform (https://www.betransparent.be).
Les informations concernant le soutien d’Intercept aux associations de patients en Belgique peuvent être trouvées en consultant le site de la Transparence belge (https://www.betransparent.be).
Intercepts Unterstützungen an Patientenorganisationen in Belgien finden Sie auf der Belgischen Transparenzplattform (https://www.betransparent.be).
Intercept has supported the following patient organizations in Belgium during calendar year 2018. Information about this is subject to change and will be updated from time to time, usually once a year.
Intercept heeft de volgende patiëntenverenigingen gesteund in België in het jaar 2018. Deze informatie kan veranderen en zal regelmatig bijgewerkt worden, gewoonlijk op jaarlijkse basis.
Intercept a appuyé les associations de patients suivantes en Belgique pendant l’année civile 2018. Les informations à ce propos sont susceptibles de changer et seront mises à jour de temps à autre, généralement une fois par an.
Intercept hat im Kalenderjahr 2018 folgende Patientenorganisationen in Belgien unterstützt. Die Informationen sind nicht endgültig und werden von Zeit zu Zeit, in der Regel jährlich, aktualisiert.
Patiëntenvereniging | Bedrag | Doel van de betaling |
| European Liver Patients' Association | €7,200 | Financiële ondersteuning voor standruimte op de EASL NAFLD Summit in september 2018. |
Association de patients | Montant | Objet du paiement |
| European Liver Patients' Association | €7,200 | Soutien financier pour le stand réservé lors du congrès EASL NAFLD de septembre 2018. |
Patientenorganisation | Betrag | Verwendungszweck |
| European Liver Patients' Association | €7,200 | Finanzielle Unterstützung für Standflächen beim EASL NAFLD-Gipfel im September 2018. |
You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.
You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.
Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.
United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)
Exploring Racial Differences and Disparities in PBC Care
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.
Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.
For all other inquiries please contact: info@interceptpharma.com